Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLF plus sintilimab neoadjuvant therapy in resectable locally advanced gastric cancer
ChiCTR2300075960Phase 2Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Sep 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, paclitaxel, oxaliplatin and fluorouracil in gastric cancer (GC) and gastric adenocarcinoma, sponsored by Huashan Hospital. Primary endpoints: pathological complete response rate and major pathological response rate. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
sintilimabpaclitaxeloxaliplatinfluorouracil
03
Conditions
gastric cancer (GC)gastric adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300075960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075960.